CC-94676- (Celgene)
Description: A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CC-94676 In Subjects With Metastatic Castration-Resistant Prostate Cancer
Target Patient Population: Prostate Cancer
Study Design: Drug is given orally daily.